Effect of severe renal impairment on umeclidinium and umeclidinium/vilanterol pharmacokinetics and safety: a single-blind, nonrandomized study

BACKGROUND: Umeclidinium and vilanterol, long-acting bronchodilators for the treatment of chronic obstructive pulmonary disease, are primarily eliminated via the hepatic route; however, severe renal impairment may adversely affect some elimination pathways other than the kidney. OBJECTIVES: To evalu...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehta, Rashmi, Hardes, Kelly, Brealey, Noushin, Tombs, Lee, Preece, Andrew, Kelleher, Dennis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279609/
https://www.ncbi.nlm.nih.gov/pubmed/25565796
http://dx.doi.org/10.2147/COPD.S68094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279609/
https://www.ncbi.nlm.nih.gov/pubmed/25565796
http://dx.doi.org/10.2147/COPD.S68094

Ejemplares similares